8-K: Ginkgo Bioworks Shifts Focus, Divests Biosecurity Unit

Ginkgo Bioworks announced its Q4 and full year 2025 financial results, revealing a strategic pivot towards autonomous labs and the divestiture of its biosecurity business.

Summary

• Total revenue for the fourth quarter of 2025 was $33 million, a 24% decrease from $44 million in the comparable prior year period.
• Full year 2025 total revenue reached $170 million, down 25% from $227 million in the prior year.
• The GAAP net loss for full year 2025 improved to $(313) million, compared to $(547) million in the prior year.
• Adjusted EBITDA for full year 2025 improved to $(167) million, from $(293) million in the prior year.
• Ginkgo has agreed to sell its biosecurity business to a consortium of investors in exchange for a minority equity position, with the transaction expected to close in the first half of 2026.
• The company is strategically focusing its investments on autonomous labs offerings, planning to expand its frontier autonomous lab in Boston to include over 50 Reconfigurable Automation Carts (RACs), with 50 more expected by the end of 2026.
• Ginkgo projects a total cash burn of $(150) million to $(125) million for the full year 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed bag; while financial performance shows continued losses and revenue decline, the strategic divestiture and focus on autonomous labs, coupled with significant contract wins, indicate a clear path forward and potential for future growth.

Positives

• GAAP net loss for full year 2025 improved significantly to $(313) million from $(547) million in 2024.
• Adjusted EBITDA for full year 2025 improved to $(167) million from $(293) million in 2024.
• Maintained a strong cash, cash equivalents, and marketable securities balance of $423 million as of December 31, 2025.
• The divestiture of the biosecurity business allows for greater flexibility and additional resources for that unit, while enabling Ginkgo to focus its cash investment on the autonomous labs business.
• A collaboration with OpenAI, utilizing GPT-5 to design experiments, resulted in a 40% improvement over the state-of-the-art in Cell-Free Protein Synthesis.
• Secured a $47 million contract with the Pacific Northwest National Laboratory for a 97-instrument autonomous lab following a successful pilot program.
• Winning new deals across Agriculture, Pharma, and the U.S. Government, providing a strong revenue base for future growth.

Negatives

• Fourth quarter 2025 total revenue decreased 24% to $33 million from $44 million in the comparable prior year period.
• Full year 2025 total revenue decreased 25% to $170 million from $227 million in the prior year.
• Full year 2025 Cell Engineering revenue decreased 24% to $133 million from $174 million in the prior year, or 3% excluding non-cash deferred revenue releases.
• Full year 2025 Biosecurity revenue decreased 30% to $37 million from $53 million in the prior year.
• Ongoing program rationalization as part of restructuring activities contributed to the decrease in Cell Engineering revenue.
• The company expects a total cash burn of $(150) million to $(125) million in 2026.

Risks

• Ability to realize near-term and long-term cost savings associated with site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities.
• Volatility in the price of Ginkgo's securities due to factors such as changes in competitive and highly regulated industries, variations in competitor performance, and changes in laws and regulations affecting the business.
• The risk of downturns in demand for products using synthetic biology.
• Uncertainty regarding the demand for passive monitoring programs and biosecurity services.
• Changes to the biosecurity industry, including advancements in technology, emerging competition, and evolution in industry demands, standards, and regulations.
• The outcome of any pending or potential legal proceedings against Ginkgo.
• Ability to realize the expected benefits from and the success of platform programs and assets.
• Ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables.
• The product development, production, or manufacturing success of customers.
• Exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration received for services.
• The potential negative impact on the business from restructuring or the failure to realize the anticipated savings associated with it.
• Uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from U.S. government shutdowns.

Future Outlook

Ginkgo expects to focus its investments on its autonomous labs business in 2026, aiming to extend its current lead in technology and commercialize its cloud lab services and custom autonomous lab installations for customers. The company projects a total cash burn of $(150) million to $(125) million for the full year 2026.

Management Comments

• "This year, we are going to focus on investing to win in the category of autonomous labs." Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
• "There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research." Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
• "There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo." Jason Kelly, CEO of Ginkgo Bioworks.
• "This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgos cash investment on our autonomous labs business." Jason Kelly, CEO of Ginkgo Bioworks.

Industry Context

StockSavvy.ai notes that Ginkgo's strategic pivot towards autonomous labs aligns with the broader industry trend of integrating AI and robotics into scientific research and development, a move that could enhance efficiency and accelerate discovery in biotechnology. The divestiture of the biosecurity unit allows for a more focused approach in a competitive landscape where specialized defense tech is attracting significant private capital.

Comparison to Industry Standards

• Ginkgo's collaboration with OpenAI, leveraging GPT-5 for experiment design and achieving a 40% improvement in Cell-Free Protein Synthesis, demonstrates a leading edge in AI-driven biological R&D compared to traditional lab methods.
• The $47 million contract with Pacific Northwest National Laboratory for a 97-instrument autonomous lab positions Ginkgo as a significant provider of advanced lab automation infrastructure, comparable to specialized engineering firms but with a unique biological focus.
• The shift from early-stage to large/enterprise customers reflects a maturation in market strategy, similar to other platform technology providers seeking more stable and larger-scale engagements.

Legal Proceedings

• The outcome of any pending or potential legal proceedings against Ginkgo is a risk factor.
• Securities litigation costs, net of insurance recovery, were included in merger and acquisition related expenses for non-GAAP adjustments.

Related Party Transactions

• Deferred revenue includes $98 thousand and $795 thousand from related parties as of December 31, 2025 and 2024, respectively.
• Non-current deferred revenue includes $64,787 thousand and $72,260 thousand from related parties as of December 31, 2025 and 2024, respectively.
• Cell Engineering revenue includes related party revenue of $8,784 thousand for the year ended December 31, 2025.
• Accounts receivable includes $357 thousand from related parties for the year ended December 31, 2025.
• Deferred revenue, current and non-current, includes $(8,147) thousand from related parties for the year ended December 31, 2025.
• Non-cash revenue for 2024 included $4.5 million from the release of deferred revenue associated with the termination of a contract with a related party.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from a focused strategy on autonomous labs, but near-term revenue declines and cash burn may cause volatility. Ginkgo will participate in the upside of the new biosecurity entity as a shareholder.
• Employees: Restructuring activities and program rationalization may impact employees, though the strategic focus on autonomous labs could create new opportunities.
• Customers: Enhanced R&D capabilities through autonomous labs and cloud services, potentially leading to faster and more efficient biological engineering solutions.
• Creditors: Continued net losses and projected cash burn could be a concern, though a strong cash position of $423 million provides a buffer.

Next Steps

• Complete the divestiture of the biosecurity business in the first half of 2026.
• Expand the frontier autonomous lab in Boston to include over 50 RACs, with 50 more expected by the end of 2026.
• Decommission the majority of Ginkgo's lab benches, walk-up automation, and workcells, moving R&D services onto a single, large autonomous lab.
• Continue commercializing autonomous labs through cloud lab services and building systems for customers.
• Host a videoconference on February 26, 2026, at 4:30 p.m. ET to discuss results and outlook.

Key Dates

Recommendation

While Ginkgo Bioworks reported significant revenue declines for both Q4 and the full year 2025, the company also demonstrated improved net loss and Adjusted EBITDA, alongside a clear strategic pivot towards autonomous labs and the divestiture of its biosecurity business. This strategic shift, coupled with notable contract wins and a strong cash position, suggests a potential for future growth and improved efficiency. However, the continued cash burn and revenue contraction warrant a cautious approach. A "hold" recommendation allows investors to observe the execution of the new strategy and its impact on financial performance before making further investment decisions.

Keywords

Ginkgo Bioworks, DNA, autonomous labs, cell engineering, biosecurity divestiture, synthetic biology, AI in biotech, robotics in labs, Q4 2025 earnings, full year 2025 results, cash burn, GAAP net loss, Adjusted EBITDA, OpenAI collaboration, PNNL contract